DeepMed Research

Zhejiang Cancer Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.zchospital.com

Clinical Trials

Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma (HCC)

Interventions: Drug: Adebrelimab, Oxaliplatin, Fluorouracil,Leucovorin

First Posted Date: 2024-12-18

Last Posted Date: 2025-02-11

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 10

Registration Number: NCT06741020

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Pharmacokinetic Study of Tranexamic Acid

Not Applicable

Recruiting

Conditions: Ovarian Neoplasm Epithelial

First Posted Date: 2024-12-11

Last Posted Date: 2024-12-11

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT06728670

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Different Intraoperative Blood Pressure Management on Postoperative Cognitive Function in Tumor Patients（PRECISION）

Not Applicable

Recruiting

Conditions: Tumor
Stroke

Interventions: Drug: Norepinephrine or phenylephrine

First Posted Date: 2024-12-02

Last Posted Date: 2024-12-02

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 214

Registration Number: NCT06711432

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Postoperative Analgesia Between Paravertebral Block and Epidural Block in Esophageal Surgery

Not Applicable

Recruiting

Conditions: Pain Syndrome
Dizziness
Vomiting
Itching
Sweet Syndrome
Cold
Satisfaction, Patient

Interventions: Drug: Liposomal bupivacaine
Drug: Bupivacaine Hydrochloride

First Posted Date: 2024-11-26

Last Posted Date: 2024-12-30

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 132

Registration Number: NCT06704698

Locations: 🇨🇳
Jiangling Wang, Hangzhou, Zhejiang, China

RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL

Phase 2

Recruiting

Conditions: Double-expressor Lymphoma

Interventions: Drug: RLC-CRCHOP

First Posted Date: 2024-11-05

Last Posted Date: 2024-11-18

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 44

Registration Number: NCT06674096

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Phase 1

Recruiting

Conditions: Metastatic HER2 Positive Gastroesophageal Junction Cancer

Interventions: Drug: cadonilimab
Drug: Trastuzumab
Drug: Disitamab Vedotin
Drug: XELOX
Drug: mFOLFOX6

First Posted Date: 2024-10-21

Last Posted Date: 2024-10-21

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 90

Registration Number: NCT06650332

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer

Not Applicable

Recruiting

Conditions: Ovarian Cancer
Cytoreductive Surgery
Depressive Symptom

Interventions: Drug: esketamine
Drug: placebo

First Posted Date: 2024-10-03

Last Posted Date: 2025-01-27

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 568

Registration Number: NCT06624878

Locations: 🇨🇳
Zhejiang cancer hospital, Hangzhou, Zhejiang, China

GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC

Phase 2

Not yet recruiting

Conditions: Nasopharynx Cancer

Interventions: Drug: GEP (Gemcitabine, Recombinant Human Endostatin, and Carrellizumab) Combined With High-low-dose Radiotherapy

First Posted Date: 2024-09-25

Last Posted Date: 2024-09-25

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 41

Registration Number: NCT06611826

CtDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: a Single-center, Randomized, Controlled Study

Phase 3

Recruiting

Conditions: Colon Cancer
Colon Cancer (stage II &amp;amp; III)

Interventions: Drug: 6-month adjuvant chemotherapy with 5-FU monotherapy
Drug: XELOX intensive treatment group

First Posted Date: 2024-09-24

Last Posted Date: 2024-09-24

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 312

Registration Number: NCT06609551

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens

Phase 1

Recruiting

Conditions: HER2-positive Gastric Cancer
HER2-positive Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Disitamab Vedotin(RC48) Plus Tratuzumab

First Posted Date: 2024-08-27

Last Posted Date: 2024-08-27

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 35

Registration Number: NCT06572319

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy